PCM
AURA icon

Prelude Capital Management’s Aura Biosciences AURA Stock Holding History

Prelude Capital Management’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.3K Hold
13,000
– – 0.01% 1120
2026
Q1 		$87K Sell
13,000
-37,000
-74% -$212K 0.01% 1074
2025
Q4 		$273K Hold
50,000
– – 0.02% 844
2025
Q3 		$309K Buy
+50,000
New +$327K 0.02% 717

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Prelude Capital Management's AURA Position: Q2 2026 in Review

Prelude Capital Management held its Aura Biosciences (AURA) position steady in Q2 2026 at 13,000 shares worth $92.3K. The position accounts for 0.01% of the portfolio, ranked #1120.

Prelude Capital Management first reported a position in AURA in Q3 2025 and has held it in 4 quarters since. The position peaked at $309K in Q3 2025. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Prelude Capital Management held 13,000 shares of Aura Biosciences worth $92.3K as of Q2 2026.
  • Prelude Capital Management left its Aura Biosciences share count unchanged in Q2 2026.
  • Aura Biosciences made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1120 holding.
  • Prelude Capital Management first reported a position in Aura Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Prelude Capital Management's Aura Biosciences position peaked at $309K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.